Company / Operating Cash Flow
Terns Pharmaceuticals, Inc. Operating Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$70.0M
FY2024
5-year range
-$70.0M / -$29.8M
FY2020-FY2024
Trend
-3.9%
vs FY2023
Sector context
#107 of 215
Health Care
What the data says
At -$70M, Terns Pharmaceuticals, Inc.'s operating cash flow ranks #107 of 215 in the Health Care sector. Operating Cash Flow has declined for 4 consecutive years, from -$30M in FY2020 to -$70M in FY2024.
Based on SEC 10-K filings.
-$70M in FY2024.
Declined from -$49M to -$70M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 215 in Health CareTop 50% of 215This company -$70.0M Sector average $661.2M
▼
-110.6% below sector average
Key checks
Key Insights
- Terns Pharmaceuticals, Inc.'s operating cash flow has declined for 4 consecutive years.
- In FY2024, operating cash flow decreased 3.9% year-over-year.
- Ranks #107 out of 215 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$70.0M | -3.9% |
| FY2023 | -$67.4M | -37.2% |
| FY2022 | -$49.1M | -17.4% |
| FY2021 | -$41.8M | -40.3% |
| FY2020 | -$29.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026